Nxera Pharma Beheer

Beheer criteriumcontroles 2/4

De CEO Nxera Pharma is Chris Cargill, benoemd in Mar2022, heeft een ambtstermijn van 2.67 jaar. bezit rechtstreeks 0.046% van de aandelen van het bedrijf, ter waarde ¥ 47.36M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.7 jaar en 5.7 jaar.

Belangrijke informatie

Chris Cargill

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.7yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	2.7yrs
Gemiddelde ambtstermijn bestuur	5.7yrs

Recente managementupdates

Recent updates

Nxera Pharma Co., Ltd. (TSE:4565) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing

Sep 25

Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable

Jun 26

Is Nxera Pharma (TSE:4565) A Risky Investment?

Apr 06

Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Mar 08

Analyse CEO-vergoeding

Hoe is Chris Cargill's beloning veranderd ten opzichte van Nxera Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-JP¥4b
Jun 30 2024	n/a	n/a	-JP¥10b
Mar 31 2024	n/a	n/a	-JP¥9b
Dec 31 2023	n/a	n/a	-JP¥7b
Sep 30 2023	n/a	n/a	-JP¥3b
Jun 30 2023	n/a	n/a	JP¥2b
Mar 31 2023	n/a	n/a	JP¥1b
Dec 31 2022	JP¥292m	JP¥88m	JP¥382m
Sep 30 2022	n/a	n/a	-JP¥383m
Jun 30 2022	n/a	n/a	-JP¥224m
Mar 31 2022	n/a	n/a	JP¥100m
Dec 31 2021	JP¥231m	JP¥65m	JP¥1b
Sep 30 2021	n/a	n/a	JP¥1b
Jun 30 2021	n/a	n/a	JP¥1b
Mar 31 2021	n/a	n/a	JP¥1b
Dec 31 2020	JP¥157m	JP¥53m	JP¥1b
Sep 30 2020	n/a	n/a	-JP¥2b
Jun 30 2020	n/a	n/a	-JP¥1b
Mar 31 2020	n/a	n/a	-JP¥332m
Dec 31 2019	JP¥101m	JP¥40m	JP¥1b

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Chris redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de JP markt.

Compensatie versus inkomsten: De vergoeding van Chris is gestegen terwijl het bedrijf verliesgevend is.

CEO

Chris Cargill (40 yo)

2.7yrs

Tenure

JP¥292,000,000

Compensatie

Mr. Christopher Cargill, also known as Chris, serves as Representative Executive Officer, President, Chief Executive Officer and Director at Nxera Pharma Co., Ltd. (formerly known as Sosei Group Corporatio...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Shinichi Tamura	Founder & Chairman of the Board	19.4yrs	JP¥332.00m	0.66% ¥ 675.1m
Christopher Cargill	Representative Executive Officer	2.7yrs	JP¥292.00m	0.046% ¥ 47.4m
Hironoshin Nomura	Executive Officer	2.7yrs	geen gegevens	0.0016% ¥ 1.6m
Toshihiro Maeda	Executive VP & COO	less than a year	geen gegevens	geen gegevens
Kieran Johnson	Executive Officer	2.7yrs	geen gegevens	0.0077% ¥ 7.8m
Kazuhiko Yoshizumi	Executive Officer	6.8yrs	geen gegevens	0.0093% ¥ 9.5m
Shinichiro Nishishita	VP of Investor Relations & Head of Regulatory Disclosures	no data	geen gegevens	geen gegevens
Stacey Southall	Associate Director & Head of Biophysics	no data	geen gegevens	geen gegevens
Candelle Chong	Executive Officer	1.7yrs	geen gegevens	0.0063% ¥ 6.5m
Patrick Branch	Head of Business Development for Japan and the APAC region	less than a year	geen gegevens	geen gegevens
Makoto Sugita	President of Nxera Pharma Japan & Exe Officer	less than a year	geen gegevens	geen gegevens
Matthew Barnes	Hd. of Drug Disc. & UK R&D	2.7yrs	geen gegevens	0.0031% ¥ 3.2m

2.7yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4565 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Shinichi Tamura	Founder & Chairman of the Board	19.4yrs	JP¥332.00m	0.66% ¥ 675.1m
Christopher Cargill	Representative Executive Officer	2.7yrs	JP¥292.00m	0.046% ¥ 47.4m
Malcolm Weir	Member of Scientific Advisory Board	1.2yrs	JP¥134.00m	geen gegevens
Rolf Kristian Berndtson Soderstrom	Independent External Director	4.7yrs	geen gegevens	0.016% ¥ 16.3m
Tomohiro Tohyama	Independent External Director	13.4yrs	geen gegevens	0.057% ¥ 58.2m
Noriaki Nagai	External Independent Director	5.7yrs	geen gegevens	0.038% ¥ 38.8m
Kuniaki Kaga	Independent External Director	6.4yrs	geen gegevens	0.040% ¥ 40.4m
David Roblin	Independent External Director	6.4yrs	geen gegevens	0.0073% ¥ 7.4m
Paul Leeson	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Peter Bernstein	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Richard Henderson	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Miwa Seki	External Independent Director	2.7yrs	geen gegevens	0.013% ¥ 12.8m

5.7yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4565 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.7 jaar).

Nxera Pharma Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Nxera Pharma Co., Ltd. Appoints Makoto Sugita as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer of Nxera Pharma

Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC

Sosei Group Corporation, Annual General Meeting, Mar 27, 2024

Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer

Sosei Group Corporation, Annual General Meeting, Mar 23, 2023

Sosei Group Corporation, Annual General Meeting, Mar 24, 2022

Recent updates

New minor risk - Share price stability

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nxera Pharma Co., Ltd. Appoints Makoto Sugita as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer of Nxera Pharma

Nxera Pharma Co., Ltd. (TSE:4565) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing

Nxera Pharma Co., Ltd. to Report Q3, 2024 Results on Nov 01, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable

Nxera Pharma Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568

Is Nxera Pharma (TSE:4565) A Risky Investment?

Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC

Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease

Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Sosei Group Corporation to Report Q1, 2024 Results on May 09, 2024

Now 24% undervalued after recent price drop

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sosei Group Corporation, Annual General Meeting, Mar 27, 2024

Now 21% overvalued after recent price rise

Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer

New minor risk - Shareholder dilution

Sosei Group Corporation Announces Marketing Approval for PIVLAZ (Clazosentan Sodium) 150 Mg in South Korea

Sosei Group Corporation to Report Fiscal Year 2023 Results on Feb 13, 2024

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Idorsia Pharmaceuticals Japan Ltd. Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for the Approval of Daridorexant

Price target decreased by 9.0% to JP¥2,281

Consensus revenue estimates increase by 12%

Sosei Group Corporation to Report Q3, 2023 Results on Nov 10, 2023

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

Second quarter 2023 earnings released: JP¥8.01 loss per share (vs JP¥17.95 loss in 2Q 2022)

Price target increased by 8.2% to JP¥2,443

Sosei Group Corporation (TSE:4565) entered into an agreement to acquire Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd (SWX:IDIA) for JPY 65 billion.

Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia

Now 38% undervalued after recent price drop

Consensus EPS estimates fall by 30%

New major risk - Share price stability

Price target decreased by 16% to JP¥2,957

Sosei Group Corporation to Report Q2, 2023 Results on Aug 04, 2023

Price target increased by 8.9% to JP¥3,500

Now 21% undervalued

Consensus EPS estimates increase by 30%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 39%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sosei Group Corporation, Annual General Meeting, Mar 23, 2023

Sosei Group Corporation to Report Fiscal Year 2022 Results on Feb 14, 2023

Third quarter 2022 earnings released: EPS: JP¥3.82 (vs JP¥5.80 in 3Q 2021)

Third quarter 2022 earnings released: EPS: JP¥3.82 (vs JP¥5.80 in 3Q 2021)

Sosei Group Corporation to Report Q3, 2022 Results on Nov 11, 2022

Price target increased to JP¥2,950

Second quarter 2022 earnings released: JP¥17.95 loss per share (vs JP¥14.11 loss in 2Q 2021)

Sosei Heptares' Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development Under Multi-Program Collaboration with Neurocrine Biosciences

Consensus revenue estimates increase by 18%

Cancer Research UK and Sosei Heptares Signs Agreement to Advance Cancer Immunotherapy Candidate into Clinical Trials

Sosei Group Corporation to Report Q2, 2022 Results on Aug 10, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 15%

Price target decreased to JP¥2,600

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Sosei Group Corporation, Annual General Meeting, Mar 24, 2022

Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19

Consensus revenue estimates increase to JP¥16.5b

Price target increased to JP¥2,767

Third quarter 2021 earnings released: EPS JP¥5.80 (vs JP¥5.94 in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: JP¥14.11 loss per share (vs JP¥17.76 loss in 2Q 2020)